Status:
COMPLETED
Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Collaborating Sponsors:
LEO Pharma
Conditions:
Lymphoma
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In cancer, the incidence of venous thromboembolism (VTE) is particularly high in patients with myeloma, especially when it is de novo and treated with thalidomide, lenalidomide or erythropoietin. Curi...
Eligibility Criteria
Inclusion
- Body weight between 40 and 100 kg
- Patient:
- 2a- With multiple myeloma indication with de novo standard treatment thalidomide or lenalidomide or erythropoietin (group 1) 2b- Or hospitalized for aggressive lymphoma treated with chemotherapy (group 2) 2c- Or older than 40 years and hospitalized at least three days for an acute medical pathology type of acute respiratory or cardiac (group 3) decompensation
Exclusion
- Patient requiring anticoagulant therapy at curative doses
- Patients with a lower platelet count 80 G / L
- Subject with a history of heparin-induced thrombocytopenia
- Subject with a history of hemorrhagic disease
- History of severe trauma within 6 weeks prior to enrollment
- Organic lesion at risk of bleeding
- Poor renal with creatinine clearance \<30 ml / min
- Hypersensitivity to Tinzaparin
- Events or bleeding tendencies associated with coagulation disorders
- Subject on oral anticoagulant
- For group 3: Presence of hematological malignancy or active cancer
Key Trial Info
Start Date :
April 14 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 9 2017
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT02260414
Start Date
April 14 2015
End Date
May 9 2017
Last Update
May 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Saint-Etienne
Saint-Etienne, France, 42055